Type 2 Diabetes Ozempic Type 1 Diabetes Insulin Complications Medications Weight Loss Insulin Delivery GLP-1 Receptor Agonists Cell Therapy Vision Problems Diabetes Mellitus Wound Healing GLP-1 Medications Natural Remedies Semaglutide Insulin Regulation Mounjaro Pharmaceuticals Weight Loss Drugs Medication Prescription Medication Metabolic Disorders Diet Chronic Conditions Space Medicine Weight Loss Treatments Incretin-based Therapies Inflammation Treatment Drug Development Genetics Insulin Resistance Treatment Options Diabetes Treatment Research Studies
Want to see what podcasts are saying about this topic? Search across 145K+ podcasts. Explore Radar
The agency cleared the label on Aug. 28, 2026 after Lilly’s head‑to‑head SURPASS‑CVOT showed a modest cardiovascular advantage over Trulicity, a result that broadens Mounjaro’s clinical and commercial role.
